Infimmune is dedicated to discovering and advancing early-stage assets that hold the promise of fundamentally transforming the lives of individuals affected by autoimmune diseases. Founded by clinicians aware of a significant unmet need for genuinely disease-modifying treatments, we aim to intervene in the early stages of pathogenesis and make a meaningful impact on patients’ lives.
WHY CHOOSE US?
NOVEL THERAPEUTICS
We are currently considering a number of novel therapeutic mAbs aiming to be either best-in-class or first-in-class across a range of autoimmune and oncological conditions. Although associated with higher development costs, and higher risks, novel therapeutic molecules have a tremendous potential for very high investment returns and can transform clinical and therapeutic practice.